Impel NeuroPharma scores $67.5 mln Series D
Seattle-based Impel NeuroPharma, a developer of therapies that treat central nervous system disorders with unmet medical needs, has raised $67.5 million in Series D financing. KKR and Norwest Venture Partners led the round with participation from return backers Vivo Capital, 5AM Ventures and venBio Partners.
6 December 2018•1 min read
